(Note: This is NOT an IPO. This is a NASDAQ uplisting from the OTCQB Market, where the common stock trades under the symbol “TOWTF”. The company’s common stock also trades on the Canadian Securities Exchange (“CSE”) under the symbol “TO”, and the Frankfurt Stock Exchange (the “FRA”) under the symbol “1P3N”. A reverse share split […]

(Note: This IPO is an initial public offering of common stock – under the proposed symbol “LIPO” – for listing on the NASDAQ – plus one non-tradeable, non-listed warrant to buy a share of common stock.) We are a clinical-stage biotechnology company focused on developing new drugs by reformulating the active agents in existing generic […]

(Note: This is a unit IPO. Felicitex Therapeutics Inc. revised the terms of its unit IPO in an S-1/A filing dated Oct. 31, 2022, by changing the composition of the units. Each unit now consists of one share of common stock and two warrants – each to buy one share of common stock. The Oct. […]

We intend to focus our search for target companies on financial technology (FinTech) and property technology (PropTech) businesses in the Nordic region and the Asia Pacific (APAC) region, especially the South Pacific.  These target companies will include businesses that offer technology solutions, technology software, services or products to the financial services or real estate industries where […]

We are a holding company. (Incorporated in the British Virgin Islands)  As a holding company with no material operations, our operations are conducted by our indirect wholly owned subsidiary, Global Engine Limited (“GEL”), in Hong Kong, a special administrative region of the People’s Republic of China (the “PRC”). This is an offering of the Ordinary Shares […]

Note: EMulate Therapeutics withdrew its plans for an IPO in a letter to the SEC dated July 31, 2024. The biotech filed confidentially for an IPO in May 2022 and followed up with its S-1 filing in August 2022. EMulate Therapeutics filed terms for its small-cap IPO on Jan. 4, 2023. We are on a mission […]

We are a developer, manufacturer, marketer, exporter and retailer of a growing beverage portfolio of 60 formulations across 13 alcoholic and non-alcoholic brands for which we own exclusive manufacturing rights. Our focus is on premium and super premium brands. (Incorporated in Australia) Our flagship Australian Bitters Company (ABC) brand accounted for approximately 75% of our revenues […]

Li Bang International Corporation Inc.  was incorporated in the Cayman Islands on July 8, 2021. We conduct all of our operations in China through our Operating Subsidiaries in China. (Incorporated in the Cayman Islands)  The main business of our Operating Subsidiaries is to design, develop, produce and sell stainless steel commercial kitchen equipment in China […]

(Note: This is an Israeli company’s unit IPO. Each unit consists of one share of stock and two warrants, each to buy one share of stock.) We are a deep-tech development-stage company that aims to disrupt fluid transportation. We are committed to improving and optimizing the global infrastructure of water, oil and gas pipeline transportation […]

(Note:  This is an IPO of American Depositary Shares to be listed on the NASDAQ. Each ADS represents one ordinary share.)      We seek to leverage our nationally recognized award-winning luxury homes and our strong market position in the luxury residential property market in Tokyo and Kanagawa prefecture to create a global transaction platform […]